Skip to main content
OpenTrials

Clinical trial condition

Perivascular Epithelioid Cell Neoplasms

Explore clinical trials studying Perivascular Epithelioid Cell Neoplasms. Study availability and eligibility vary by location and protocol.

48 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Perivascular Epithelioid Cell Neoplasms trial results

Completed

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

NCT03525834

Conditions
Angiomyolipoma, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +26 more
Locations
  • Novartis Investigative Site Wuhan, Hubei, China
  • Novartis Investigative Site Shanghai, Shanghai Municipality, China
  • Novartis Investigative Site Chengdu, Sichuan, China
  • Novartis Investigative Site Beijing, China
View Trial Details
Completed

Glutamine PET Imaging in LAM

NCT04388371

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Vanderbilt University Medical Center Nashville, Tennessee, United States
View Trial Details
Completed

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

NCT01059318

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Center for LAM Research and Clinical Care Boston, Massachusetts, United States
  • University of Cincinnati, Department of Internal Medicine, Pulmonary, Critical Care & Sleep Medicine, Cincinnati, Ohio, United States
  • Novartis Investigative Site Lyon, France
  • Novartis Investigative Site Milan, Italy
View Trial Details
Completed

Safety of Simvastatin in LAM and TSC

NCT02061397

Conditions
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +24 more
Locations
  • University of Pennsylvania Philadelphia, Pennsylvania, United States
View Trial Details
Completed

LAM Pilot Study With Imatinib Mesylate

NCT03131999

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Columbia University New York, United States
  • Medical University of South Carolina Charleston, South Carolina, United States
View Trial Details

Related conditions